Pretreatment hemoglobin adds prognostic information to the nccn-ipi in patients with diffuse large b-cell lymphoma treated with anthracycline-containing chemotherapy

Michael R. Clausen, Matthew J. Maurer, Sinna Pilgaard Ulrichsen, Thomas S. Larsen, Bodil Himmelstrup, Dorthe Rønnov-Jessen, Brian K. Link, Andrew L. Feldman, Susan L. Slager, Grzegorz S. Nowakowski, Carrie A. Thompson, Per Trøllund Pedersen, Jakob Madsen, Robert S. Pedersen, Jette Sønderskov Gørløv, James R. Cerhan, Mette Nørgaard, Francesco D’amore

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Background: Hemoglobin (Hgb) concentration at diagnosis is associated with outcome in cancer. In a recently reported simplified 3-factor prognostic score in Hodgkin lymphoma, Hgb, along with age and clinical stage, outperformed the classical International Prognostic Score with seven parameters. Methods: In the present study, we investigated if pretherapeutic Hgb concentration added prognostic information to the NCCN-IPI in diffuse large B-cell lymphoma. We included patients from the Danish Lymphoma Registry (LYFO; N = 3499) and from the Molecular Epidemiology Resource (MER; N = 1225), Mayo Clinic and University of Iowa. Four sex-specific Hgb groups were defined: below transfusion threshold, from transfusion threshold to below lower limit of normal, from lower limit of normal to the population mean, and above the mean. We used multivariable Cox regression to estimate the hazard rate ratios (HR) and 95% CIs for overall survival (OS) and event-free survival (EFS), adjusting for sex, NCCN-IPI, comorbidity, and rituximab treatment. Results: Approximately half of the patients had Hgb levels below the lower limit of normal. Compared to patients with Hgb levels above the mean, an inferior OS was directly correlated with lower pretreatment Hgb within the predefined groups (HR=1.23, HR=1.51, and HR=2.05, respectively). These findings were validated in the MER. Conclusion: Based on multivariable analysis, lower pretreatment Hgb, even within the normal range but below the mean, added prognostic information to established indices such as the NCCN-IPI and the Charlson comorbidity index.

Original languageEnglish (US)
Pages (from-to)987-996
Number of pages10
JournalClinical Epidemiology
Volume11
DOIs
StatePublished - 2019

Keywords

  • Diffuse large B-cell lymphoma
  • Hemoglobin
  • NCCN-IPI
  • Prognosis

ASJC Scopus subject areas

  • Epidemiology

Fingerprint Dive into the research topics of 'Pretreatment hemoglobin adds prognostic information to the nccn-ipi in patients with diffuse large b-cell lymphoma treated with anthracycline-containing chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Clausen, M. R., Maurer, M. J., Ulrichsen, S. P., Larsen, T. S., Himmelstrup, B., Rønnov-Jessen, D., Link, B. K., Feldman, A. L., Slager, S. L., Nowakowski, G. S., Thompson, C. A., Pedersen, P. T., Madsen, J., Pedersen, R. S., Gørløv, J. S., Cerhan, J. R., Nørgaard, M., & D’amore, F. (2019). Pretreatment hemoglobin adds prognostic information to the nccn-ipi in patients with diffuse large b-cell lymphoma treated with anthracycline-containing chemotherapy. Clinical Epidemiology, 11, 987-996. https://doi.org/10.2147/CLEP.S219595